# A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

> **NCT06546280** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT06546280
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2026-08-26
- **Final completion:** 2026-09-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06546280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06546280, "A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06546280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*